Form 8-K - Current report:
SEC Accession No. 0001104659-25-076214
Filing Date
2025-08-11
Accepted
2025-08-11 17:00:40
Documents
13
Period of Report
2025-08-11
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2523144d1_8k.htm   iXBRL 8-K 33075
2 EXHIBIT 99.1 tm2523144d1_ex99-1.htm EX-99.1 10295
  Complete submission text file 0001104659-25-076214.txt   214154

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA btai-20250811.xsd EX-101.SCH 3047
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE btai-20250811_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btai-20250811_pre.xml EX-101.PRE 22380
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2523144d1_8k_htm.xml XML 3562
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

EIN.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)